Toll-like receptors (TLRs) initiate and maintain host defenses and inflammation, and directly contribute to diseases such as atherosclerosis. It is not completely understood in what cell types proatherogenic TLR-induced signaling arises and, particularly, there is uncertainty regarding the potential functional role of TLR2 in endothelial cells (ECs). We determined TLR2 and TLR4 gene expression in four different human and two different murine primary ECs using gene array analysis, RT-PCR, and flow cytometry and confirmed these data by functional studies by stimulating ECs with the corresponding TLR ligands. TLR4 was expressed in all human and murine ECs and these cells responded to stimulation with LPS. Faint expression of TLR2 was observed in human ECs, whereas murine ECs express considerable amounts of TLR2 mRNA. Human ECs failed to respond to TLR2 ligands while murine ECs responded to TLR2 ligands. Furthermore, in murine ECs, TLR2 was located on the cell surface while in human ECs, TLR2 was sequestered in intracellular compartments. After IFN-γ or IL-1β stimulation, TLR2 translocated to the cell surface of human ECs. In conclusion, TLR2 is expressed intracellularly in human ECs and, therefore, TLR2 ligands are inaccessible to the receptor. Murine ECs express membrane TLR2 and respond to TLR2 ligands, but human ECs normally will not respond unless they are first primed with inflammatory stimulation, which appears to trigger translocation of TLR2 to the cell surface.
INTRODUCTION
The innate immune system is the first line of defense against invading micro-organism. Immune competent cells (such as macrophages, dendritic cells, neutrophils, and endothelial cells) recognize highly conserved, pathogen-associated molecular patterns (PAMPs) on the surface of a wide variety of pathogens, as diverse as Gram-positive and Gram-negative bacteria, viruses, fungi, and mycoplasma. Toll-like receptors belong to a family of germ-line encoded pattern recognition receptors expressed on many immune competent cells. Upon binding of their cognate ligands, TLRs recruit several adaptor molecules to their intracellular signaling domain, leading to the activation of several kinases that ultimately results in the activation of NF-κB and other immune-responsive genes. 1 Atherosclerosis has been linked to infectious origins, but the underlying mechanisms have not been elucidated. Important clues regarding potential molecular causes have now emerged from studies in experimental animal models, which increasingly show significant intercommunication among signaling pathways central to immune defenses, lipid metabolism, and chronic inflammation. [2] [3] [4] We and others independently reported that atherosclerosis-prone apolipoprotein E (apoE)-deficient mice that are also lacking the gene encoding MyD88 develop markedly less atherosclerosis compared to apoE -/-
MyD88
+/+ litter-mate controls. 5, 6 Also, apoE -/-
TLR4
-/-mice develop less atherosclerosis compared to control apoE -/-
+/+ mice, but the reduction is less impressive. 5 One likely explanation relates to the fact that multiple TLRs and IL-1 receptor all depend upon MyD88. Hence pro-atherogenic stimuli might well converge on MyD88 from a number of directions, and TLR4 may be just one of several sources; another may be TLR2.
Both in vitro and in vivo studies have suggested that TLR2 is another source of pro-atherosclerotic stimuli that depend upon MyD88 to promote development of atheromata, 7, 8 and that ligands interact with TLR2 expressed specifically by vascular endothelial cells (ECs) to promote atherosclerosis. 8 Dunzendorfer et al. 7 reported that, under anti-atherogenic in vitro laminar flow conditions, human coronary artery ECs express only low levels of TLR2 mRNA and protein, but that TLR2 expression was up-regulated by low shear stress, which tends to be pro-atherogenic. Mullick et al. 8 found that Ldlr -/-TLR2 -/-mice exhibited a modest decrease in atherosclerotic plaque. Reconstitution of TLR2 expression in bone marrow cells of these double knock-out mice had no effect on atherosclerosis, which led these investigators to conclude that the proatherogenic triggers were unidentified endogenous ligands interacting with TLR2 expressed by vascular ECs. However, this conclusion was not supported by any direct evidence, and TLR2 expression by ECs was not determined. Furthermore, we and others have previously shown that human ECs which express very low levels of TLR2 do not respond to TLR2 ligands, but that TLR2 is up-regulated by LPS, various pro-inflammatory cytokines, and histamine. [9] [10] [11] [12] We and others have documented the expression of TLR4, TLR1, TLR2 and, to a lesser extent, TLR5 in human atherosclerotic plaques. 13, 14 A fundamental prerequisite for attributing a proatherogenic role for EC expression of TLR2 is a clear demonstration that vascular ECs do in fact express significant amounts of TLR2, and that the receptor responds to known TLR2 ligands by increased expression of pro-inflammatory mediators. Here, we report the results of a detailed analysis of TLR2 expression by six different primary EC types (four derived from the human and two from the mouse) and a functional analysis of TLR2 response by those ECs. Our results indicate that there are marked differences between human and murine ECs, and that human ECs do not express significant amounts of TLR2 on the cell surface rendering them unresponsive to TLR2 ligands. Therefore, data obtained from murine models regarding the role of TLR2 in atherogenesis should be cautiously extrapolated to the development of atherosclerosis in the human.
MATERIALS AND METHODS

Cells and reagents
Human coronary artery endothelial cells (HCAECs), human aortic endothelial cells (HAECs), human pulmonary artery endothelial cells (HPAECs), and human umbilical vein endothelial cells (HUVECs) were obtained from Cambrex (Walkersville, MD, USA) and cultured according to the manufacturer's recommendations. HCAECs, HAECs, and HPAECs were used for experiments from passages 4-6. HUVECs were used for experiments from passages 2-6. Immortalized human dermal microvessel endothelial cells (HMECs) were described previously. 9 HMECs were used for experiments from passages 6-8. RAW 264.7 and HEK293 cells were obtained from the American Type Culture Collection and were cultured in DMEM supplemented with 10% heat-inactivated FBS, 2 mM glutamine, penicillin, and streptomycin. Murine aortic endothelial cells (MAECs) from C57BL/6 and TLR2 knock-out mice were isolated (> 95% purity) and maintained as previously described. 5 MAECs were used for experiments from passages 5-7. Murine lung endothelial cells (MLECs) were isolated from C57BL/6 and TLR2 knock-out mice. In brief, excised lungs were minced with a razor blade and suspended in 10 ml Hank's Balanced Salt Solution (HBSS; Invitrogen) supplemented with 100 µg/ml Blendzyme (Roche Applied Science, Indianapolis, IN, USA) and incubated for 45 min at 37°C. After digestion, the cells were filtered through a 100-µm cell strainer, centrifuged at 1000 rpm for 4 min and red blood cell lysis buffer (eBioscience; San Diego, CA, USA) was added. The cells were resuspended in ice-cold MACS buffer (Miltenyi Biotec; Auburn, CA, USA) and washed once. Next, cells were incubated with biotinylated anti-CD31 antibody (0.25 µg per 10 6 cells; eBioscience) for 5 min at 4°C. After washing, cells were resuspended in MACS buffer and incubated with 20 µl anti-biotin microbeads (Miltenyi Biotec) for 15 min at 4°C. Following incubation, cells were applied to an equilibrated MS column, washed once and bound cells were collected in 1 ml MACS buffer. The cells were cultured on gelatin-coated tissue culture plates (BD Bioscience; Bedford, MA, USA) in endothelial cell growth medium 2 (Promocell; Heidelberg, Germany). Purity of the MLEC isolation was determined by DiI-AcLDL (Molecular Probes; Carlsbad, CA, USA) uptake and eNOS staining. Purity of lung endothelial cell isolations was routinely greater than 90%. MLECs were used for experiments from passages 3-6.
Functional studies in human and murine ECs
Endothelial cells were plated at 5000 cells per well in 96-well-plates 24 h prior to stimulation. Supernatants were harvested 24 h after stimulation with the TLR ligands.
The following TLR ligands were used at the concentration indicated: FSL-1 (InvivoGen; San Diego, CA, USA), Pam 2 and Pam 3 (Bachem; Torrance, CA, USA), poly(I:C) (Amersham Biosciences; Piscataway, NJ, USA), LPS, LCCWE, 15 flagellin, CpG, and Loxoribine (InvivoGen). The cytokine concentrations in cell culture supernatants were analyzed by ELISA using OptEIA™ mouse IL-6, mouse TNF-α, human IL-6, human IL-8 (BD Biosciences; Franklin Lakes, NJ, USA), and mouse DuoSet™ MCP-1 (JE/CCL2) (R&D Systems; Minneapolis, MN, USA). Data are representative of at least three independent experiments performed in quadruplicate and are reported as mean values ± SD.
Toll-like receptor signaling pathway gene arrays
Total RNA from HCAECs, HAECs, HUVECs, HPAECs, and HMECs were isolated using RNeasy mini kit (Qiagen; Valencia, CA, USA) and probed to human Toll-like receptor signaling pathway cDNA gene array according to the manufacturer's recommendations (SuperArray Bioscience Corporation; Frederick, MD, USA). Analysis of the images and quantification was performed using the GEArray Expression Analysis Suite (SuperArray Bioscience Corporation) software, and genes of interest were normalized to the house-keeping gene GAPDH.
Flow cytometry analysis
Cell surface staining was performed on RAW 264.7 cells, MAECs and MLECs using anti-mouse TLR2-FITC (eBioscience) and anti-mouse TLR4-PE (eBioscience) antibodies. Appropriate isotype IgG (eBioscience) controls were used. Cells were either permeabilized or non-permeabilized prior to staining with antibodies. Permeabilization of the cells was performed using the Cytofix/Cytoperm plus™ Kit (BD Biosciences). Cell surface and intracellular staining were performed on HMECs, HCAECs, HAECs, HPAECs, HUVECs and THP-1, and HEK293 cells using FITC-conjugated mouse anti-human TLR1, TLR2, TLR4 and TLR6 antibodies (eBioscience). Isotype-matched control antibodies were used as controls. Resting and INF-γ or IL-1β (both R&D Systems) stimulated HUVECs were stained with anti-mouse TLR2-FITC for cell surface and intracellular expression. Cells were analyzed on a FACSCalibur™ flow cytometer (BD Biosciences) using CELLQuest™ software.
RT-PCR and real-time PCR
Total RNA was isolated from HCAECs, HAECs, HUVECs, HPAECs, HMECs, RAW 264.7 cells, MAECs, and MLECs using the RNeasy mini kit (Qiagen). Following reverse transcription with the Omniscript cDNA synthesis kit (Qiagen), PCR analysis was performed using primers specific for human CD36 (sense, GGCTGTCATTGGTGCTGTCC; antisense, GCTGCCACAGCCAGATTGAG) and mouse CD36 (sense, TGCTGGAGCTGTTATTGGTG; antisense, CAGCTGCTACAGCCAGATTC). The PCR was performed using Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA) under the following conditions: 30 cycles of 30 s at 94°C, 30 s at 60°C, and 30 s at 72°C. Amplification of β-actin served as a control. The human TLR6 was amplified by using primers 5′-GAAGAATG-GTAAAGTCCC-3′ and 5′-AGTTTTCACATCATC-CTC-3′, and TLR1 PCR was performed by using primers 5′-GGCACGTTAGCACTGAGACTC-3′ and 5′-GGTGGATATTCTTATTGCTGTGTG-3′. GAPDH served as a control. For real-time PCR analysis, total RNA was subjected to DNase treatment (Invitrogen) according to the manufacturer's instructions to eliminate possible DNA contaminations. DNase-treated total RNA was reserve transcribed as described above. Sequences for human TLR2 and β-actin primers/probes were published previously. 16, 17 Real-time PCR was performed on an iCycler (Bio-Rad). Duplicates differing by less than one cycle were averaged and the amount of transcript was analyzed by the Ct method for each sample and expressed as relative expression.
Western blot analysis
HAEC, HUVEC, HPAEC, HMEC lysates were separated by SDS-PAGE and transferred onto PVDF membranes. Non-specific binding was blocked by overnight incubation of membranes with 5% dry milk powder (Bio-Rad). The membranes were then probed with anti-CD36 antibody (Santa Cruz Biotechnology) at a dilution of 1:400 or p38 antibody (dilution of 1:1000) as a loading control. After washing, specific bands were visualized by chemiluminescence (ECL, Amersham).
RESULTS
Gene array analysis reveals a low expression of TLR2 mRNA in resting human endothelial cells, which are unresponsive to TLR2 ligands
We first analyzed the expression of TLR2 in four different primary human endothelial cell types (HCAECs, HAECs, HPAECs, HUVECs) and one human endothelial cell line (HMECs) using gene array analysis. While all human endothelial cells express TLR4 mRNA, expression of TLR2 mRNA was low or undetectable (Fig. 1A) . To confirm the gene array data, we performed real-time PCR analysis. TLR2 expression in human ECs is detectable at low levels compare to TLR2-expressing THP-1 cells (Fig. 1B) . HUVECs and HMECs display the highest expression of TLR2 amongst human EC types examined. Next, we determined if these different human endothelial cells respond to several TLR2 ligands (FSL-1, Pam 2 , Pam 3 , LCCWE). As shown in Figure 2 , all five human ECs are unresponsive to different TLR2 ligands as measured by IL-6 and IL-8 secretion into the supernatant. In contrast, all human ECs responded to stimulation with TLR4 (LPS), TLR3 (poly(I:C)), or TLR5 (flagellin) ligands with cytokine or chemokine secretion ( Fig. 2A,B) . However, TLR2 ligands signal through TLR2/TLR1 (Pam 3 ) or TLR2/TLR6 (Pam 2 , FSL-1) heterodimers, and ligands for different heteromeric complexes may cause distinct signaling. None of the TLR2 ligands tested resulted in a secretion of IL-6 ( Fig. 2A) or IL-8 ( Fig. 2B ) in the five human ECs. Recently, CD36 has been shown to be a co-receptor for TLR2 in the recognition of LTA. 18 It is conceivable that human ECs do not respond to TLR2 ligands because they lack CD36 expression. To exclude this possibility, we evaluated the expression of CD36 in ECs by RT-PCR. We found that both human and murine ECs do indeed express CD36 mRNA (Fig. 3A) . CD36 was also observed by Western blot analysis (Fig. 3B ) using an anti-human CD36 antibody. Human ECs exhibited a strong expression of CD36 protein. These results led us to the conclusion that the lack of TLR2 signaling is due to a very low expression of TLR2 mRNA in human ECs that is not sufficient to allow a functional response to TLR2 ligands.
Primary murine endothelial cells express TLR2 mRNA and respond to stimulation with TLR2 ligands
To determine if murine ECs also lack expression of TLR2 mRNA and resemble thereby human ECs, we isolated murine aortic endothelial cells (MAECs) from wild-type and TLR2-deficient mice as described previously. 5 RT-PCR from MAECs derived from wild-type mice revealed robust TLR2, TLR4, and MD-2 mRNA expression (Fig. 4A, left panel) . In contrast to human ECs, wild-type MAECs responded to TLR2 ligands with secretion of IL-6 ( Fig. 4B ) and MCP-1 (Fig. 4C) . MAECs derived from TLR2 -/-mice were unresponsive to TLR2 ligands, as expected. We also observed strong responses to LPS, poly (I:C), and flagellin in both wildtype and TLR2-deficient mice, confirming that MAECs from TLR2-deficient mice respond to other TLR ligands. To determine whether other vascular murine ECs also respond to stimulation with TLR2 ligands, we isolated murine ECs from the lung blood vessels. Murine lung ECs (MLECs) from wild-type and TLR2-deficient mice were isolated as described in Material and Methods. The purity of MLECs was determined by eNOS staining and DiI AcLDL uptake and was consistently greater than 90% A B (Fig. 4A , middle and right panels). Confirming our data from MAECs, MLECs also responded to stimulation with TLR2 ligands with IL-6 secretion (Fig. 4B ). In contrast, MLECs isolated from TLR2 -/-mice were unresponsive to TLR2 but responsive to TLR3, TLR4, and TLR5 ligands (Fig. 4B) , indicating their functional responsiveness apart from lack of TLR2 signaling.
Primary murine endothelial cells express TLR2 on the cell surface but human endothelial cells do not
Next, we determined if the lack of TLR2 response in human ECs is associated with lack of TLR2 protein expression in human ECs. Five human EC types were stained with TLR2 and TLR4 antibodies and analyzed by flow cytometry. THP-1 cells are known to express TLR2 and TLR4 on the cell surface and, therefore, served as a positive control. HEK293 cells do not express TLRs and served as a negative control. Flow cytometry indicated that none of the human EC types expressed TLR2 on the cell surface (Fig. 5A) . As previously reported, 19 human ECs also do not express TLR4 on the cell surface but intracellularly (Fig. 5A ). To our surprise, when flow cytometry studies were repeated following permeabilization prior to staining, human EC expression of TLR2 was comparable in magnitude to expression of TLR4 (Fig. 5B) .
Next, we determined if murine ECs express TLR2 on the cell surface. RAW 264.7 cells served as a positive control for surface expression of TLR2 and TLR4 (Fig. 6A,B) . MLECs isolated from wild-type mice showed expression of TLR2 on the cell surface, but TLR4 was only expressed intracellularly (Fig. 6A,B) . MLECs isolated from TLR2 -/-mice showed neither expression of TLR2 on the cell surface nor in the intracellular compartment, and served as negative control for TLR2 staining (Fig. 6A) .
Human ECs express TLR1 and TLR6 mRNA and protein
The studies above indicate that resting human ECs only express TLR2 intracellularly, and that this is the likely reason why human ECs do not respond to stimulation with TLR2 ligands. TLR2 requires co-receptors for initiation of signaling upon encounter with TLR2 ligands. Heterodimers of TLR1/2 or TLR2/6 are required to recognize tri-acetylated and di-acetylated lipopeptides, respectively. [20] [21] [22] [23] Interaction with the corresponding ligand induces a signaling cascade that ultimately results in the activation of NF-κB. We investigated the expression of TLR1 and TLR6 in human ECs to determine if a possible lack of expression of the corresponding co-receptor is responsible for the unresponsiveness of human ECs to TLR2 ligands. Data derived from RT-PCR suggested that the TLR1 and TLR6 mRNA do express in human ECs (Fig. 7A) . Analysis of the protein expression of TLR1 and TLR6 by flow cytometry demonstrated that both receptors are detectable in the cytoplasm of human ECs and not on the cell surface (Fig. 7B,C) . These results suggest that the unresponsiveness of human ECs to TLR2 ligands is not due to lack of TLR1 or TLR6 presence in these cells.
Taken together, the most likely interpretation of these data is that TLR2 surface expression is required to allow EC detection of TLR2 ligands and signaling and that the differential expression pattern of TLR2 in human versus mouse ECs may explain the differential responses observed in these cell types to TLR2 ligands. Therefore, we conclude that while TLR4 is functionally and topologically similar in human and mouse ECs, there are distinct differences in TLR2 localization between human and mouse ECs that significantly impact the response to TLR2 ligands.
IFN-γ or IL-1β stimulation induces TLR2 translocation to the cell surface in human ECs
We stimulated HUVECs with IFN-γ (20 ng/ml) for 16 h, and performed flow cytometry using antibodies against TLR2. THP-1 cells and HEK293 cells (which do not express TLRs) served as positive and negative controls, respectively. Flow cytometry indicated that prior to IFN-γ stimulation, HUVECs express TLR2 only intracellularly (Fig. 8A, dashed line) . IFN-γ stimulation of HUVECs resulted in expression of TLR2 on the cell surface (Fig. 8A, bold line) . The flow cytometry studies were repeated following permeabilization prior to staining, and showed that TLR2 was expressed mainly intracellularly in resting cells and further increased following IFN-γ stimulation (Fig. 8B) . Next, we stimulated HUVECs with the pro-inflammatory cytokine IL-1β (100 ng/ml) for 16 h and analyzed the surface expression of TLR2 and TLR4. IL-1β stimulation of HUVECs resulted in increased surface expression of TLR2 and, to an even greater extent, TLR4 on the cell surface (Fig. 8C) . Flow cytometry analysis on permeabilized HUVECs revealed that, while the majority of TLR4 is translocated to the cell surface upon stimulation with IL-1β, only a fraction of TLR2 is translocated to the surface in response to IL-1β and the majority remains intracellular (Fig. 8D) . 
A DISCUSSION
Both in vitro studies and investigations using atherosclerosis-prone mice have directly demonstrated the participation of TLR signaling through the common MyD88 adaptor in the etiology of atherosclerosis. 5, 6, 8 However, proatherogenic effects of TLR signaling could be due to TLR stimulation in ECs, vascular smooth muscle cells, mononuclear phagocytes, other cells derived from the hematopoietic lineage, or any combination of these cell types. Determining which cell type(s) are responsible for pro-atherogenic effects triggered by TLR signaling remains an important unanswered question. Some studies suggest the possibility that TLR2 signaling in ECs may be at least one culprit. For example, Mullick et al. recipients. Because no differences in the amount of atherosclerotic plaque between these two groups of mice were found, these authors concluded that TLR2 expressed by vascular ECs was most likely pro-atherogenic. However, some previous studies suggest that functional TLR2 is not expressed by human vascular ECs. 10 Our results provide an explanation that reconciles conflicting results on expression and function of TLR2 in vascular ECs among different species.
We show here that there are definite, important interspecies differences in TLR2 expression by vascular ECs. In mouse ECs, TLR2 is expressed on the cell surface, has ready access to extracellular ligands, and can trigger increased expression of known TLR2 gene targets by exposure to TLR2 ligands. However, in resting human 
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ECs, most TLR2 protein is expressed in intracellular compartments, where it may not respond to TLR2 ligands. Both human and murine ECs express TLR4 in intracellular compartments, but TLR4 ligands can nevertheless gain access to these receptors, trigger TLR4-dependent signaling, and cause increased expression of TLR4 gene targets. 19, 24 TLR4-independent uptake of LPS has not only been demonstrated for ECs, but also for epithelial cells. 25, 26 These data are most consistent with the interpretation that extracellular TLR2 ligands can stimulate TLR2 expressed on the cell surface by murine ECs, but may have no effect on human ECs because of the low levels of surface expression of TLR2 in resting human 
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ECs. Our results are consistent with, and extend, our previous data that show that human ECs do not respond to TLR2 ligands. 10 However, we demonstrate here that murine ECs express TLR2 on the cell surface and do respond to TLR2 ligands. Our data contrast with previous studies showing that HCAECs weakly express surface TLR2, but respond to TLR2 ligand. 19, 27 Under anti-atherogenic conditions of laminar flow, HCAECs expressed low levels of TLR2 mRNA and protein and expression of both increased under conditions of low shear stress. 7 On the other hand, Liang et al. 28 reported no change in very low baseline levels of TLR2 expression in ECs with low shear stress. A clue to the resolution of these discordant findings came from studies showing that human ECs can respond to TLR2 ligands if they are first primed, for example by stimulation with TLR4 ligand, inflammatory cytokines, or histamine. 10, 11, 29 We propose that the explanation may be that priming of human ECs alters the sequestration of TLR2 and mobilizes the receptor to the cell surface where TLR2 ligands can directly interact with their cognate receptors and result in functional responses. Indeed, we could demonstrate C that stimulation of HUVECs with IFN-γ or IL-1β mobilizes TLR2 to the cell surface. Dunzendorfer et al. 7, 19 reported that stimulation of HCAECs with combinations of LPS, IFN-γ or TNF-α and IFN-γ greatly up-regulates TLR2 surface expression (19% in unstimulated versus over 90% in stimulated HCAECs). Several TLRs reside in different compartments within the cells. [30] [31] [32] [33] [34] While receptors for bacterial or viral nucleic acids can directly encounter the pathogens' DNA or RNA in the cytoplasm of the host cell, intracellular TLR4 requires uptake of LPS 19, 24 for signaling. In this study, we show that intracellular expression of TLR2 is not sufficient to induce signal transduction in human ECs. Our data are consistent with previous findings by Triantafilou et al. 35, 36 demonstrating that surface expression of TLR2 is required for signal transduction while receptor internalization is neither sufficient nor necessary for TLR2-mediated activation.
Our results may have implications in extrapolating results from experimental mouse models of atherosclerosis. TLR2 ligands might produce different results in mice than in humans. Mullick et al. 8 concluded that TLR2 expression in ECs is particularly important since bone marrow transplants of TLR2 -/-bone marrow into Ldlr -/-recipients had no effect on the extent of atherosclerosis compared to TLR2 +/+ bone marrow transplants. However, translating those results to potential clinical therapies may not be straightforward. Based on the results from Mullick et al., 8 a reasonable prediction would be that pretreatment of mice with TLR2 antagonists would prevent the development of atherosclerosis. However, unless human ECs are primed and express functional cell-surface TLR2, treatment with TLR2 antagonists may not have a significant effect on clinical atherosclerosis. Once human ECs are primed by proinflammatory cytokines or other stimuli and TLR2 is upregulated on the cell surface, TLR2 might be involved in the progression of atherosclerosis rather than initiation. However, we emphasize that our study did not address in vivo atherosclerosis. The potential implications are intriguing and, therefore, further studies are needed to address more directly the questions our findings raise. Consistent with our current findings, expression of several TLR orthologues, namely TLR2, TLR3, TLR4, and TLR9, markedly varies between mice and humans. Available evidence also increasingly indicates that there are other interspecies differences in TLR signaling networks. These differences include variable expression of TLR transcripts in different cell types, dissimilar transcriptional regulation upon cellular activation 37, 38 and variations in receptor utilization by the same ligand. 31 As a consequence, in vivo work with TLR9 ligands is now increasingly performed in non-human primates. 39 Our results thus appear consistent with a growing realization that there are significant interspecies differences in TLR expression patterns and signaling modalities; hence, results from certain studies in experimental models such as rodents may not necessarily be directly applicable to human diseases.
CONCLUSIONS
There are important differences between murine and human EC expression of TLR2 leading to differential responses to TLR2 ligands. Namely, murine but not human vascular ECs express cell surface TLR2 that can respond to TLR2 agonists. Human vascular ECs express very weak TLR2 mRNA, and TLR2 protein is sequestered in intracellular compartments, which precludes endothelial cell responses to TLR2 ligands in the resting stage.
